GastroEsophageal Cancer Clinical Trial
Official title:
Esophageal Stent With or Without Anti-migration Device for Tumors of the Gastroesophageal Junction: Multicenter Randomized Controlled Study. ANTIMIG Study
The aim of this prospective, controlled, randomized, multicentre, single-blind study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally advanced or metastatic malignant stenosis of the gastroesophageal junction.
In order to reduce the rate of spontaneous intragastric migration of esophageal stent placed for gastroesophageal junction tumor, anti-migration device has been developed. Pilot studies suggest the absence of morbidity of this device, but no comparative study has been conducted to confirm the interest of this anti-migration device. The aim of this study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally advanced or metastatic malignant stenosis of the gastroesophageal junction. - Main objective: To evaluate the rate of intragastric migration of 2 types of esophageal stents (one with and the second without anti-migration device) placed for malignant stenosis of the gastroesophageal junction. - Secondary objective(s): - Degraded migration rate (M3 and M6) if patient alive, and duration of survival without dysphagia - Comparison of the morbidity of these two stents - Comparison of the effectiveness of these two stents on dysphagia and reflux - Clinical and technical failure rate of these two stents This is a prospective, controlled, randomized, multicentre, single-blind study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04544046 -
Supportive Oncology Care At Home RCT
|
N/A | |
| Not yet recruiting |
NCT04555304 -
Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
|
Phase 2 | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Completed |
NCT04099641 -
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04385641 -
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
|
N/A | |
| Completed |
NCT03165994 -
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
|
Phase 2 | |
| Active, not recruiting |
NCT03279237 -
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
|
Phase 1 | |
| Completed |
NCT03321630 -
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
|
Phase 2 | |
| Completed |
NCT02853474 -
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03983954 -
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT06138223 -
The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)
|
N/A | |
| Active, not recruiting |
NCT03647969 -
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT05122091 -
Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03720678 -
A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
|
Phase 1 | |
| Completed |
NCT02317991 -
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
|
Phase 2 | |
| Completed |
NCT02013154 -
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
|
Phase 1 | |
| Terminated |
NCT05395052 -
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06356311 -
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
|
Phase 3 | |
| Active, not recruiting |
NCT03490292 -
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
|
Phase 1/Phase 2 |